RCEHealth CareCompany Update19 Aug 202619 August 2026· 2 min read
Recce Pharmaceuticals (ASX: RCE) Wins Approval for Phase 3 Comparator Study
Recce Pharmaceuticals will add a 208-patient, active-controlled study to its Australian Phase 3 R327G program. An interim analysis is planned after 104 participants.